Key Drivers
- Strong liquidity
- High R&D burn
- Elevated multiples
AIAI Summary
Arrowhead's shift from a binary clinical bet to an early commercial-stage company makes execution—REDEMPLO prescription conversion and payer reimbursement—alongside the upcoming SHASTA/plozasiran Phase‑3 readout the primary drivers of near-term valuation rather than clinical probability alone. Monitor REDEMPLO revenue/payer wins and the Phase‑3 topline closely: positive outcomes justify the rich multiples, while weak uptake or failed readouts would likely cause sharp repricing and heighten dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High R&D burn
- •Elevated multiples
ARWR shows improving profitability and ample liquidity but is constrained by heavy R&D burn, significant debt, and elevated valuation multiples. #HighR&D
Price Behavior
Key Price Behavior Insights:
- •Below last-month MA
- •Near recent low
- •Potential mean-reversion
ARWR is trading below its last month moving average after pulling back from the March 4 swing high toward the March 12 low, indicating short-term weakness with support at the March 12 low and resistance at the March 4 highs.
Pullback from
Sentiment & News
Key News Insights:
- •Q3 clinical catalysts
- •Busy investor calendar
- •Citi stake cut
Arrowhead is scheduling heavy investor engagement and guiding multiple Q3 clinical readouts (SHASTA‑3/4, RNAi dimer, ARO‑MAPT) that could drive momentum while a large Citi share sale signals shifting institutional ownership amid sustained industry interest in RNAi.
Positive near‑term data flow could re‑rate the stock if readouts are favorable, but the Citi reduction highlights potential short‑term institutional caution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings